Healthcare
China Medical & HealthCare Group Limited(COLRF)
Live Price
Offline$0.08
+0.00% today
1Y Change
+0.00%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $1.13B
- Revenue Growth
- +3.7%
- EPS Growth
- +117.2%
- Dividend Yield
- 1.9%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
China Medical & HealthCare Group Limited (COLRF) is a Healthcare stock with a market cap of $1.13B and listed on OTC. The stock last traded around $0.08 and up 0.0% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +3.7%, EPS growth of +117.2%, a dividend yield of 1.9%. What stands out right now is revenue +3.7%, EPS +117.2%, free cash flow -155.0% with operating margin 3.8% and ROIC 1.8%. The dividend is present but secondary, with a yield around 1.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.7. Stock Foundry combines COLRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+3.7% vs +7.6% peer median
Operating Margin
Below sector median
+3.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on May 20, 2025, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +3.7% and EPS at +117.2%, with operating margin around 3.8%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.9%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 May 20, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Mar 10, 2025 | โ | +0.0% | +0.0% | +0.0% |
2024 Aug 2, 2024 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Edge
COLRF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
COLRF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
COLRF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for COLRF and SPY.
Company Overview
China Medical & HealthCare Group Limited
OTC
Tian An Medicare Limited is an investment holding company that operates an integrated platform for healthcare and eldercare services primarily in the People's Republic of China and the Asia Pacific region. It focuses on the investment, management, and operations of healthcare and eldercare businesses, including a comprehensive spectrum of medical and senior care services delivered through subsidiaries. Notable operations encompass the Nanjing Tongren Hospital and Kunming Tongren Hospital, alongside eldercare facilities managed via Aveo China. The company also engages in related property investment and development to support its service offerings. Additionally, Tian An Medicare Limited participates in securities trading, investment activities, and the provision of financial services, diversifying its portfolio within the healthcare sector. Classified in the medical care facilities industry, it serves customers seeking specialized healthcare and eldercare solutions. Headquartered in Wan Chai, Hong Kong, Tian An Medicare Limited plays a key role in addressing the growing demand for integrated health services in the region.
- Employees
- 2.7k
- Street Address
- Rooms 1904B-5, 19/F, Allied Kajima Building No. 138 Gloucester Road
- Mailing
- Wan Chai
- Region
- Wan Chai, Hong Kong
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 10.3
- Price/Sales
- 0.7
- Price/Book
- 0.6
Growth
- Revenue
- +3.7%
- EPS
- +117.2%
- Free Cash Flow
- -155.0%
Profitability
- Gross Margin
- 13.8%
- Operating Margin
- 3.8%
- Net Margin
- -1.6%
- ROE
- -1.5%
- ROIC
- 1.8%
Balance Sheet
- Debt/Equity
- 0.50
- Current Ratio
- 2.15
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.